Answers are grounded in this paper and cite their sources.
• Enhancing T cell infiltration in glioblastoma (GBM) while overcoming its immunosuppressive tumor microenvironment (TME) is high great of clinical importance. • Key strategies include targeting myeloid-derived suppressor cells (MDSCs) to reduce immunosuppression and repolarizing tumor-associated macrophages (TAMs) from an M2 (immunosuppressive) to an M1 (pro-inflammatory) phenotype to boost T cell function. • Administering chemokines can recruit more effector T cells to the tumor site, and combining immune checkpoint inhibitors (ICIs) with other therapies can enhance T cell activity. • Addressing the immunosuppressive factors in the TME, such as TGF-β and IL-10, is crucial for improving the effectiveness of immunotherapies in GBM. This review focuses on enhancing T-cell infiltration in glioblastoma (GBM) while overcoming its immunosuppressive tumor microenvironment (TME). Key strategies include targeting myeloid-derived suppressor cells (MDSCs) to reduce immunosuppression and repolarizing tumor-associated macrophages (TAMs) from an M2 (immunosuppressive) phenotype to an M1 (proinflammatory) phenotype to increase T-cell function. Administering chemokines can help attract more effector T cells to the tumor site. Combining immune checkpoint inhibitors (ICIs) with other treatments can further increase T cell activity. To make immunotherapy more effective in GBM, it is also essential to address the immunosuppressive signals in the TME, such as transforming growth factor beta (TGF-β) and interleukin-10 (IL-10).
No takes yet. Share an insight, caveat, or question.
Habibi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: